News

Pharmaceutical Technology on MSN2d
EC conditionally approves Regeneron’s Lynozyfic for multiple myeloma
The EC has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody Lynozyfic for treating ...
Technology Networks1d
Linvoseltamab Wins European Approval Despite FDA Rejection
Regeneron’s bispecific antibody linvoseltamab, now branded as Lynozyfic, has received conditional approval from the European ...
PharmaTimes1d
Lynozyfic receives EU approval for relapsed multiple myeloma treatment
Regeneron Pharmaceuticals has announced that the European Commission has conditionally approved Lynozyfic (linvoseltamab) for ...
Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma
Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma Lynozyfic will provide a new option with convenient dosing and administration to ...
Fierce Pharma3d
Regeneron scores EU nod for bispecific antibody Lynozyfic, setting up clash with J&J and Pfizer
After issues at a third-party manufacturer caused the FDA to reject Regeneron's multiple myeloma bispecific antibody ...
Regeneron Pharmaceuticals (NasdaqGS:REGN) To Showcase Oncology And Respiratory Data At Major Conferences
Regeneron Pharmaceuticals (NasdaqGS:REGN) is poised for an eventful month, highlighting exciting advancements in their cancer and respiratory disease treatments at upcoming conferences. Following a ...
Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides
Regeneron boosts antibody profits with higher Dupixent sales and expands biologics production via FUJIFILM Diosynth ...
Seeking Alpha3d
Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma
Lynozyfic will provide a new option with convenient dosing and administration to patients who face cycles of relapse and remission TARRYTOWN, N.Y., April 28, 2025 (GLOBE NEWSWIRE) -- Regeneron ...